<DOC>
	<DOCNO>NCT01934647</DOCNO>
	<brief_summary>This clinical trial study safety , tolerability , pharmacodynamics single dos MK-8892 participant PAH . The primary objective estimate measure peak effect high acutely tolerate ( HAT ) single oral dose MK-8892 pulmonary vascular resistance ( PVR ) .</brief_summary>
	<brief_title>Acute Dosing MK-8892 Participants With Pulmonary Arterial Hypertension ( PAH ) ( MK-8892-003 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>postmenopausal female female reproductive potential , remain abstinent us two acceptable method birth control 14 day dose MK8892 suspect PAH classify one follow subgroup : idiopathic , heritable , drug toxininduced , associate connective tissue disease , define Dana Point 2008 Clinical Classification clinical indication right heart catheterization PAH classify World Health Organization ( WHO ) functional class II III medical history indicate secondary cause Pulmonary Hypertension ( PH ) nonincluded etiology PAH include follow test within 6 month Visit 1 : Echo indicate significant left heart disease , valvular disease , structural defect ; function test indicate significant pulmonary disease ; image test indicate venoocclusive disease ; perfusion scan indicate thromboembolic disease ; abdominal ultrasound indicate cirrhosis ; positive test human immunodeficiency virus ( HIV ) persistent permanent atrial fibrillation , significantly impair gas exchange , history radiation lung mediastinum , hepatic hepatobiliary disease , immunodeficiencies latent bleed risk estimate Glomerular Filtration Rate ( GFR ) &lt; 45 mL/min alanine aminotransferase test ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) aspartate aminotransferase test ( AST ) serum glutamic oxaloacetic transaminase ( SGOT ) &gt; = 3 x upper limit normal ( ULN ) Visit 1 systolic blood pressure ( BP ) &lt; 105 mmHg , heart rate ( HR ) &gt; 100 beats/min Visit 1 ( Day 7 1 ) previously receive specific therapy PAH within 4 week prior Visit 1 take sildenafil , valdenafil nitrate within 24 hour prior Visit 2 date take tadalafil within 7 day prior Visit 2 date take 2 specific PAH medication concomitantly within 4 week anticipate Visit 2 date . Only treatment na√Øve subject subject stable PAHspecific monotherapy endothelin receptor antagonist ( [ ERA ] ; bosentan , ambrisentan , macitentan ) prostacyclin analog ( [ PCA ] ; treprostinil , epoprostenol , iloprost ) eligible . PAH monotherapy one medication may continue without interruption study take soluble guanylate cyclase ( sGC ) activator ( riociguat ) within 24 hour anticipate Visit 2 date . take diltiazem immediate release within 1 day diltiazem extend release within 2 day prior Visit 2 date currently take potent inhibitor inducer Cytochrome P450 3A4 ( CYPA4 ) , consume &gt; 1 liter grapefruit juice per day pregnant breastfeeding expect conceive study post study followup period donate 500 mL blood within prior 60 day currently participate within prior three month participate study investigational compound device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>